Inventiva (IVA) has released an update.
Inventiva, a biopharmaceutical company, has enrolled over 85% of patients in its NATiV3 clinical trial, with strong indications of positive biomarker evolution in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company reported a cash position of €10.1 million as of mid-2024 and has extended its cash runway until mid-October 2024 after securing €20.1 million through royalty certificates. Inventiva is actively pursuing additional financing options to support its ongoing clinical trials and future operations.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
